STOCK TITAN

Integra Lifesciences Holdings Corp - IART STOCK NEWS

Welcome to our dedicated news page for Integra Lifesciences Holdings (Ticker: IART), a resource for investors and traders seeking the latest updates and insights on Integra Lifesciences Holdings.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Integra Lifesciences Holdings's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Integra Lifesciences Holdings's position in the market.

Rhea-AI Summary
Integra LifeSciences launches MicroMatrix Flex, a dual-syringe system for precise delivery of UBM technology, expanding wound reconstruction capabilities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.39%
Tags
none
-
Rhea-AI Summary
Integra LifeSciences Holdings Corporation announces CEO Jan De Witte's retirement by the end of 2024. Stuart Essig appointed as executive chairman of the Board. A search for a new CEO is underway.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.65%
Tags
management
-
Rhea-AI Summary
Integra LifeSciences (IART) reported Q4 2023 revenues of $397.0 million, a 0.2% decrease from the previous year. Full-year 2023 revenues were $1,541.6 million, a 1.0% decrease. Adjusted earnings per diluted share for Q4 were $0.89, down from $0.94 in 2022. For the full year, adjusted earnings were $3.10, compared to $3.36 in 2022. The company highlighted successful business achievements and strategic acquisitions, along with revenue growth in specific segments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.65%
Tags
earnings
Rhea-AI Summary
Integra LifeSciences Holdings Corporation (IART) is set to release its fourth quarter and full year 2023 financial results on February 28, 2024. The management team will host a conference call at 8:30 a.m. ET, with a live webcast available on the Investors section of the company's website. Participants can register for the call and access dial-in details. A webcast replay will also be available on the Investors section of the website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.39%
Tags
conferences earnings
-
Rhea-AI Summary
Integra LifeSciences Holdings Corporation (NASDAQ: IART) CEO to Present at J.P. Morgan Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary
Integra LifeSciences Holdings Corporation (Nasdaq: IART) has announced the acquisition of Acclarent, Inc. from Ethicon, Inc., a Johnson & Johnson MedTech company, for $275 million in cash at closing, subject to customary purchase price adjustments, and an additional $5 million upon the achievement of certain regulatory milestones. The acquisition will become part of Integra’s Codman Specialty Surgical (CSS) division, making Integra one of the leading providers of ENT products and technologies. The U.S. ENT specialty devices market is growing at 5-6% and will add approximately $1 billion to the CSS global total addressable market. The Acclarent portfolio includes groundbreaking balloon technologies for sinus dilation and eustachian tube dilation as well as surgical navigation systems.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.03%
Tags
acquisition
Rhea-AI Summary
Integra LifeSciences Holdings Corporation (Nasdaq: IART) appoints Jeff Graves, Ph.D., president and CEO of 3D Systems Corporation, to its board of directors. Dr. Graves brings a wealth of experience from leading and transforming technically complex businesses, including his roles at 3D Systems, MTS Systems Corporation, and C&D Technologies, Inc. His expertise in streamlining global operations and delivering differentiated solutions will be valuable to Integra's board and shareholders. With the addition of Dr. Graves, Integra has welcomed four new directors since 2021, signaling a commitment to enhancing the board's expertise and diversity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.63%
Tags
management
-
Rhea-AI Summary
Integra LifeSciences reports Q3 2023 financial results with a decline in revenues and earnings per share compared to the prior year. The company remains on track to restart the Boston manufacturing facility and has achieved milestones with the relaunch of CereLink in international markets and submission for regulatory approval in the U.S.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.97%
Tags
earnings
-
Rhea-AI Summary
Integra LifeSciences Holdings Corporation will release Q3 2023 financial results on October 25, 2023. Conference call at 8:30 a.m. ET. Webcast replay available on the Company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.48%
Tags
conferences earnings
Rhea-AI Summary
Perimeter Medical Imaging AI, Inc. appoints Adam Hodges as VP of Sales and Marketing.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.81%
Tags
management AI
Integra Lifesciences Holdings Corp

Nasdaq:IART

IART Rankings

IART Stock Data

2.72B
67.17M
13.91%
88.9%
3.21%
Analytical Laboratory Instrument Manufacturing
Manufacturing
Link
US
Princeton

About IART

integra lifesciences, a world leader in medical technology, is dedicated to limiting uncertainty for surgeons, so they can concentrate on providing the best patient care. integra offers innovative solutions in orthopedic extremity surgery, neurosurgery, spine surgery, and reconstructive and general surgery. integra's orthopedic products include devices and implants for spine, foot and ankle, hand and wrist, shoulder and elbow, tendon and peripheral nerve protection and repair, and wound repair. integra is a leader in neurosurgery, offering a broad portfolio of implants, devices, instruments and systems used in neurosurgery, neuromonitoring, neurotrauma, and related critical care. in the united states, integra is a leading provider of surgical instruments to hospitals, surgery centers and alternate care sites, including physician and dental offices. founded in 1989 integra is headquartered in plainsboro, new jersey and has over 3,500 employees worldwide. integra's common stock is li